Sustained Anlotinib Regimens Stabilize Advanced Soft Tissue Sarcoma Beyond Initial Progression
A multicenter real-world study shows continuing anlotinib-based combinations after progression achieved disease control in patients with advanced soft tissue sarcoma.




















